Center for Biologies Evaluation and Review

Center for Biologies Evaluation and Review Vaccines, regardless of manufacturing method In vivo diagnostic allergenic products Human blood products... 

Biologies (reviewed by FDA s Center for Biologies Evaluation and Review) Investigational FDA 1571... 

Food and Drug Administration. Center for biologies evaluation and review. Meeting of the Biological, Response Modifiers Advisory Committee, Bethesda, Maryland, July 15, 1999. 

Although it was recodified in 1944 and 1997/ it has remained in effect without significant change since 1902. It was initially implemented by the Public Health Service, but was transferred to FDA in 1972.Today it is implemented by the Center for Biologies Evaluation and Review (CBER) within FDA, which is located in buildings on the campus of the National Institutes of Health, where it had been located prior to the 1972 transfer to FDA. 

Once the FDA receive the initial submission, an IND reference number is assigned. The application is then passed on to the appropriate review centre either the Center for Drug Evaluation and Research (CDER), or the Center for Biologies Evaluation and Research (CBER). Various experts will then review the submitted documents, the purpose being to ensure that the safety of subjects is not compromised and, in the case of Phase II and III studies, that the quality of study design is scientifically adequate. The FDA are allowed 30 days to complete the initial review, after which the study can commence, provided that it has been approved by an Institutional Review Board (IRB). 

Source Food and Drug Administration, Center for Biologies Evaluation and Research. Chemistry, Manufacturing and Controls Review, BLA 980286, TNFKFc, Immunex, FDA, Rockville, MD, 1998. Immunex, Enbrel, http ///www.immunex.com/search/searchresults.jsp [accessed January 10,2003]. 

FDA center responsible for review Center for Drug Evaluation and Research (CDER) Center for Biologies Evaluation and Research (CBER) ... 

Center for Biologies Evaluation and Research. Manual of Standard Operating Procedures and Policies, SOPP 8411.1. Changes to an Approved Application. Administrative Handling and Review of Annual Reports, March 10,1999. 

Like other potential biopharmaceutical products, FDA, Center for Biologies Evaluation and Research (CBER) regulates the production, testing and use of AAV vectors in human clinical trials, in the US. Many regulatory documents are available to help guide the researcher. These documents are available via the Internet on http //www.fda.gov.cber/guidelines.htm. Review of these documents prior to significant work towards production of vector for... 

This FDA IND review checklist has been designed in consultation with FDA reviewers, industry consultants, and regulatory professionals to serve as a summary tool indicating the evaluative criteria used by the Center for Drug Evaluation and Research (CDER) and the Center for Biologies Evaluation and Research (CBER) to critique and assess applications received. It can be used internally as a part of the Quality Assurance process, as a guideline for regulatory development of an application, and/or as a self-assessment tool to predict likely FDA response to an application. 

The three product centers that can lead the regulatory review of a neoorgan product include Center for Devices and Radiological Health (CDHR), Center for Biologies Evaluation and Research (CBER), and the Center for Drug Evaluation Research (CDER). CDRH is responsible for regulating those products that are primarily medical devices. A medical device is defined as An instrument, apparatus, implement, machine, contrivance, implant, or other similar or related article, including a component, part, or accessory,... 

The BLA must describe all nonclinical pharmacology and toxicology studies conducted on the biologic product. These nonclinical laboratory studies include those submitted in the IND, those submitted during clinical investigations, and new nonclinical studies not previously submitted. The Center for Biologies Evaluation and Research reviews these studies to evaluate their adequacy and comprehensiveness and to ensure that there are no inconsistencies or inadequately characterized toxic effects. The application also should include information on studies not performed by the sponsor but of which the sponsor has become aware (e.g., studies in published literature). 

---